Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Mar 1;26(3):1079-1087.
doi: 10.31557/APJCP.2025.26.3.1079.

Prognostic Significance of Chaperonin-Containing Tailless Complex Polypeptide 6A (CCT6A) in Ewing Sarcoma

Eman A Saad  1 , Mona Y Y Abd Allah  1 , Suzy Abd Elamabood Abd-El-Hameed  2 , Azza Abdel-Aziz  1 , Zalata Khaled  1
Affiliations

Prognostic Significance of Chaperonin-Containing Tailless Complex Polypeptide 6A (CCT6A) in Ewing Sarcoma

Eman A Saad et al. Asian Pac J Cancer Prev. .

Abstract

Background: Chaperonin-Containing Tailless complex polypeptide 6A (CCT6A) is considered one of the biomarkers that play a role in cancer initiation, progression and resistance to body defenses and to anti-cancer drugs. Its exact prognostic role in Ewing sarcoma (ES) remains uncertain. The aim of this study is to assess immunohistochemical (IHC) expression of CCT6A in ES, and to assess the relation of its expression to different clinicopathological parameters and evaluate its prognostic significance in ES cases.

Methods: This retrospective cohort study included 35 cases diagnosed as ES at the Oncology Center of Mansoura University (OCMU), Faculty of Medicine, Egypt. Clinicopathological and survival data were collected. IHC for CCT6A was performed and correlated with clinicopathological parameters and patients' prognosis.

Results: High IHC expression of CCT6A was found in 28 cases out of the studied 35 ES cases (80%), while 7 cases only (20%) showed low CCT6A expression. High CCT6A expression showed significant association with tumor size ≥8 cm (P= 0.01), treatment with adjuvant radiotherapy either for local control, infiltrated surgical margins or poor histopathological response to chemotherapy (P= 0.01), poor histopathological response to chemotherapy (P= 0.02), and HUVOS grades I and II (P= 0.01). High CCT6A expression was found to be a predictor of shorter overall survival and was an independent poor predictive factor by multivariate analysis (P= 0.03).

Conclusion: High CCT6A expression in ES associates with large tumor size, treatment with adjuvant radiotherapy for aforementioned indications, poor histopathological response to chemotherapy, and HUVOS grades I and II. Its high expression also independently predicts poor overall survival in ES patients. It may be used as a useful biomarker to predict prognosis of ES.

Keywords: CCT6A; Ewing sarcoma; Prognosis; survival.

PubMed Disclaimer

Conflict of interest statement

The authors declare no relevant financial affiliations or conflicts of interest.

Figures

Figure 1
Figure 1
(A) A case of Ewing sarcoma showing classical morphology (H&E, ×400), (B) CD99 diffuse strong positive membranous reaction (IHC, x400), (C) ERG moderate positive nuclear reaction with strong positive nuclear reaction in endothelial cells as positive internal control (IHC, x400), (D) FLI1 moderate positive nuclear reaction with strong positive nuclear reaction in endothelial cells as positive internal control (IHC, x400), (E) NKX2.2 diffuse strong nuclear reaction (IHC, x400), (F) PAX7 diffuse strong nuclear reaction (IHC, x400).
Figure 2
Figure 2
(A and B): CCT6A low expression (IHC, x400), (C and D): CCT6A high expression (IHC, x400).
Figure 3
Figure 3
Overall Survival of the Entire Cohort Studied according to CCT6A Expression.
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Wei S, Siegal GP. Small round cell tumors of soft tissue and bone. Arch Pathol Lab Med. 2022;146(1):47–59. - PubMed
    1. Machado I, Yoshida A, López-Guerrero JA, Nieto MG, Navarro S, Picci P, Llombart-Bosch A. Immunohistochemical analysis of NKX2 2, ETV4, and BCOR in a large series of genetically confirmed Ewing sarcoma family of tumors. Pathol Res Pract. 2017;213(9):1048–53. - PubMed
    1. Koshevarova V, Kim A, Wilhelm AB, Eyzaguirre EJ, Bhargava P. Paratesticular Ewing’s sarcoma. Radiol Case Rep. 2023;18(9):3260–3. - PMC - PubMed
    1. Dupuy M, Lamoureux F, Mullard M, Postec A, Regnier L, Baud’huin M, et al. Ewing sarcoma from molecular biology to the clinic. Front Cell Dev Biol. 2023;11:1248753. - PMC - PubMed
    1. El Nadi E, El Ghoneimy A, El Shafiey M, Taha H, Zaghlool MS, Zaki I, et al. Ewing Sarcoma/Peripheral Neuroectodermal Tumor of Bone and Soft Tissue in Infants Egypt: Children Cancer Hospital of Egypt. Cancer Res J. 2021;9(1)

MeSH terms

Substances